Hayward, CA - October 1, 2002 - Biolog, Inc. announced
today that it has licensed its new Phenotype MicroArray (PM)
technology to The Institute for Genomic Research (TIGR) under
a collaborative agreement.
Phenotype MicroArrays represent a fundamental technology
platform which allows scientists to easily and efficiently
test hundreds to thousands of cellular traits simultaneously.
The technology has the promise of determining cellular phenotypic
expression in many areas of research. The two most important
near term applications are using PMs to determine the effect
and response in living cells to genetic changes and exposure
to drugs and chemicals.
TIGR will use the PM technology to understand and characterize
phenotypes of different strains of bacteria, specifically
focused on strains of Salmonella typhimurium, Streptococcus
pneumoniae, Staphylococcus aureus, Synechococcus sp. and Escherichia
coli. The phenotypic data derived from these experiments will
be interpreted in conjunction with comparative genomic and
microarray experiments being done at TIGR.
Ian Paulsen, the TIGR faculty member leading the phenotype
microarray analyses said, "We hope to be able to complement
our existing genome sequencing, bioinformatic and expression
microarray capabilities with Biolog's phenotype microarray
technology to further our understanding of microbial cell
"In our own laboratories we are demonstrating that the
PM phenotypic data alone can provide invaluable information
about how and where genes are expressing themselves in model
cell lines. It is our hope that by linking the PM results
to gene expression data we can efficiently identify how genes
are regulating various cellular pathways in these target cells"
said Barry Bochner, Vice President of R&D for Biolog,
Biolog has installed their proprietary OmniLog® System
for high-throughput kinetic analysis of the PM panels at TIGR.
The Phenotype MicroArray panels are sets of approximately
2,000 cellular assays that enable comparative analyses of
a variety of metabolic and drug sensitivity changes in cells.
TIGR will initially be testing bacterial strains. Mutant strains
will be analyzed for phenotypic changes using the PM technology
and results will then be compared to the phenotypes of the
normal cell line.
Under the terms of the agreement, TIGR and Biolog, Inc. will
share certain intellectual property rights from new discoveries
identified using the PM technology. Biolog and TIGR have agreed
to exclusively license any discoveries that have potential
commercial applications. Financial terms of the collaboration
are not being disclosed by the parties.
Biolog has an active technology-licensing program to use
the current generation of PMs for research using bacterial
and fungal model cell lines. The company is developing similar
arrays for use with mammalian cell lines.
The Institute for Genomic Research (TIGR) is a not-for-profit
research institute whose primary research interests are in
structural, functional and comparative analysis of genomes
and gene products from a wide variety of organisms including
viruses, eubacteria (both pathogens and non-pathogens), archaea
(the so-called third domain of life), and eukaryotes (plants,
animals, fungi and protists such as the malarial parasite).
Biolog, a privately held company based in Hayward, CA, is
a pioneer in the development of powerful new cell analysis
tools for solving critical problems in clinical, pharmaceutical,
and biotechnology research and development. The company's
Phenotype MicroArray technology and OmniLog® PM System
can be used in the discovery and development of new drugs
as well as bioactive agents for animal and plant applications.
Further information can be obtained at the company's website,
For more information, please contact Tim Mullane, President
& CEO, Biolog, Inc., telephone (510) 785-2564 x 319 /
or Robert Koenig, Public Affairs Manager, The Institute for
Genomic Research, telephone (301) 838-5880 / email@example.com